A ntitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Chiara Catania, Fabio Conforti, Gianluca Spitaleri, Massimo Barberis, Lorenzo Preda, Cristina Noberasco, Chiara Lazzari, Francesca Toffalorio, Filippo de Marinis, Michela Manzotti, Tommaso Martino De Pas

Research output: Contribution to journalArticlepeer-review

Abstract

We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestinal stromal tumor and also in several cases of acral and mucosal melanomas. Some of the patients with gastrointestinal stromal tumor or melanoma harboring this rare mutation have had a tumor response when treated with imatinib. In contrast, in our case, the mutation was associated with primary resistance to full doses of imatinib but, at the same time, it was not a cause of resistance to sorafenib.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalOncoTargets and Therapy
Volume7
DOIs
Publication statusPublished - May 8 2014

Keywords

  • Imatinib
  • Sorafenib
  • Thymic carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A ntitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E'. Together they form a unique fingerprint.

Cite this